<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109872</url>
  </required_header>
  <id_info>
    <org_study_id>FIS-LEN-2018-01</org_study_id>
    <nct_id>NCT04109872</nct_id>
  </id_info>
  <brief_title>Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.</brief_title>
  <official_title>Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentric, observational and retrospective study of the use of lenalidomide in
      patients with relapsed or refractory mantle cell lymphoma that are included in the RRMCL
      spanish program.

      The lenalidomide effectiveness and tolerability data will be retrospectely collected until
      the 30 of April 2018.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Experience of real clinal practice lenalidomide use.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>Results of the the usage in real clinical practice of the lenalidomide monotherapy or combination treatment in patients with relapsed or refractory mantle cell lymphoma that aren´t candidate to other alternative treatments inside the RRMCL spanish program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve objective response.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>The objective response will be measured in terms of complete response, not confirmed complete response and partial response according to the 2007 International Working Group criteria after the 6º treatment cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the response.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>Partial and complete response duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verify the disease free survival.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>The disease free survival is defined as the time that passes from the inclusion in the record until a control is done or takes place a relapse (local or distant).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verify the disease overall survival.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>The disease overall survival is defined as the time that passes from the inclusion in the record until a control is done or the patient´s death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of treatment adverse events.</measure>
    <time_frame>Start of observation period (first medical record available on site) up to last medical record available on site or the end of the observation period (31 December 2019), whichever occurred first</time_frame>
    <description>Number and description of adverse effects due to the lenalidomide treatment.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Mantle cell lymphoma treated with lenalidomide cohort</arm_group_label>
    <description>Patients diagnosed with mantle cell lymphoma treated with leanalidomide through the RRMCL spanish program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.</description>
    <arm_group_label>Mantle cell lymphoma treated with lenalidomide cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with mantle cell lymphoma that received lenalidomide through the
        RRMCL program as long as they meet all the inclusion criteria and none of the exclusion and
        independently from being dead or alive in the moment of data record.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old.

          -  Diagnosed with relapsed or refractory mantle cell lymphoma verified by a tissue
             biopsy.

          -  Treated with monotherapy or combination of lenalidomide.

          -  Not candidate for any of the therapeutic options approved until that date for this
             disease.

          -  Not candidate or unable to be included in any clinical trial due to availability or
             geographical difficulty.

          -  Registered in the RRMCL spanish program.

        Exclusion Criteria:

          -  ECOG &gt; 2.

          -  Patients with uncontrolled comorbidities.

          -  Blastoid variant.

          -  Central nervous system tumor infiltration.

          -  HIV, HBV and/or HCV active infection.

          -  Radiotherapy concomitant treatment or that have received radiotherapy in the previous
             30 days to the beginning of the first cycle of lenalidomide.

          -  Diagnosed with other active solid tumor except for basal cell carcinoma skin cancer.

          -  Patients that haven´t completed at least one complete cycle of the treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Carlos García Pérez</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos García Pérez</last_name>
    <phone>955 00 80 00</phone>
    <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos García Pérez</last_name>
      <phone>955 00 80 00</phone>
      <email>administracion.eecc.hvm.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>RRMCL spanish program</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

